Owlstone Medical
Generated by Meeveem AI
"Pioneering breath diagnostics for early disease detection and precision medicine"
Cambridge
•51 - 250 Employees
•Diagnostics
About Owlstone Medical
Owlstone Medical develops non-invasive breath diagnostic tests using its Breath Biopsy platform. The company analyses volatile organic compounds from breath samples to detect biomarkers for cancer, respiratory diseases, liver conditions, and gastrointestinal disorders, enabling earlier detection when treatments are most effective. The company offers the ReCIVA Breath Sampler and analytical services to pharmaceutical companies, healthcare providers, and research institutions globally. Partners include the NHS, Mayo Clinic, and AstraZeneca. The mission centres on saving 100,000 lives and reducing healthcare costs by $1.5 billion through accessible diagnostic technologies.
174
Team Members
2003
Founded
Diagnostics
Sector
Hybrid
Work Environment
Our Vision
A world where disease is detected at its earliest stages through simple breath analysis, enabling timely intervention and dramatically improving survival rates across cancer, respiratory, and metabolic conditions.
Our Mission
At Owlstone Medical, our mission is to save 100,000 lives and $1.5 billion in healthcare costs by advancing early detection and precision medicine through Breath Biopsy.